Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.2K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

10.6K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
10.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

764
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
764

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.

JCO precision oncology·2026
Same author

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.

Cell death & disease·2026
Same author

Oncofetal RNA-binding proteins of IGF2BP family suppress IRF-3 and NF-kB dependent transcription downstream of cytosolic RNA sensors.

bioRxiv : the preprint server for biology·2026
Same author

Establishment of Patient-Derived Organoids for Pediatric Cancer Research.

Cancers·2026
Same author

Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same author

Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia.

Blood neoplasia·2026
Same journal

Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides.

Cancer biology & therapy·2026
Same journal

<i>NSUN2</i> mediates <i>SALL2</i> m5C methylation to inhibit ferroptosis and promote breast cancer progression.

Cancer biology & therapy·2026
Same journal

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.

Cancer biology & therapy·2026
Same journal

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.

Cancer biology & therapy·2026
Same journal

Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.

Cancer biology & therapy·2026
Same journal

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude <i>versus</i> low-altitude regions: a multi-center retrospective study.

Cancer biology & therapy·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

22.2K

Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte

Francis R LeBlanc1,2, Xin Liu1, Jeremy Hengst3

  • 1a Penn State Hershey Cancer Institute; Penn State College of Medicine ; Hershey , PA USA.

Cancer Biology & Therapy
|August 8, 2015
PubMed
Summary
This summary is machine-generated.

Sphingosine kinase-1 (SPHK1) is overexpressed in large granular lymphocyte leukemia, driving cancer cell survival. Inhibiting SPHK1 with drugs like SKI-178 reduces leukemia cell viability and induces apoptosis, offering a new therapeutic strategy.

Keywords:
LGL leukemiaSKI-178,SKI-IIapoptosislarge granular lymphocytenatural killersphingosine kinase 1

More Related Videos

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells
06:55

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

Published on: February 22, 2020

19.7K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Related Experiment Videos

Last Updated: Apr 5, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

22.2K
Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells
06:55

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

Published on: February 22, 2020

19.7K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Area of Science:

  • Biochemistry
  • Oncology
  • Immunology

Background:

  • Sphingolipid metabolism is a key regulator of cancer cell survival and drug resistance.
  • Sphingosine kinase-1 (SPHK1) produces sphingosine-1-phosphate (S1P), a bioactive lipid implicated in various cancers.
  • The role of SPHK1 in large granular lymphocyte (LGL) leukemia, particularly Natural Killer (NK) cell LGL leukemia, remains unexplored.

Purpose of the Study:

  • To investigate the role of SPHK1 in NK-LGL leukemia.
  • To evaluate SPHK1 as a potential therapeutic target for NK-LGL leukemia.

Main Methods:

  • Quantification of SPHK1 and S1P levels in patient samples.
  • Treatment of leukemic cells with SPHK1 inhibitors (SKI-II, SKI-178).
  • Assessment of cell viability, apoptosis, cell cycle, and signaling pathways (JAK-STAT, Bcl-2 phosphorylation).

Main Results:

  • SPHK1 is overexpressed in LGL leukemia patients' peripheral blood mononuclear cells (PBMCs), correlating with elevated serum S1P.
  • SPHK1 inhibitors SKI-II and SKI-178 reduced leukemic NK cell viability and induced apoptosis.
  • Inhibitors restored sphingolipid balance, increased ceramide, decreased S1P, and induced G2/M cell cycle arrest.
  • SKI-178 decreased JAK-STAT signaling and induced Bcl-2 phosphorylation via CDK1.

Conclusions:

  • SPHK1 is a novel therapeutic target for NK-LGL leukemia.
  • SPHK1 inhibition demonstrates anti-leukemic effects by inducing apoptosis and restoring sphingolipid homeostasis.
  • Targeting SPHK1 may offer a promising treatment strategy for patients with NK-LGL leukemia.